DelveInsight’s “Beta Thalassemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Beta Thalassemia, historical and forecasted epidemiology as well as the Beta Thalassemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Beta Thalassemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Beta Thalassemia Market Forecast
Some of the key facts of the Beta Thalassemia Market Report:
- The Beta Thalassemia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- The Centres for Disease Control and Prevention state that beta thalassemia is very uncommon in the United States (2023)
- Even though beta thalassemia is one of the most prevalent autosomal recessive diseases worldwide, it is very uncommon in the United States. In the general community, the incidence of symptomatic cases is thought to be about 1 in 100,000 people
- Orphanet (2023) estimates that the annual incidence of symptomatic patients is 1/100,000 globally and 1/10,000 in the EU. It is unknown how often this type is
- According to Chamberlain et al. (2021), using a rough extrapolation from the Hulihan et al study, the estimated population-based prevalence of alpha- and beta-thalassemia combined in the US was 5.7/100,000
- Key Beta Thalassemia Companies: Novartis, Hoffmann-La Roche, Vertex Pharma, Bristol-Myers Squibb, Sanofi, HemaQuest Pharma, Takeda, Agios Pharmaceuticals, Silence Therapeutics, Vifor Inc., Celgene, EmeraMed, Protagonist Therapeutics, CRISPR Therapeutics, CSL Vifor, EdiGene (GuangZhou) Inc., Ionis Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Silence Therapeutics plc, Phoenicia Biosciences, Shanghai BDgene, Beam Therapeutics, EmeraMed, Regenacy Pharmaceuticals, Editas Medicine, Fulcrum Therapeutics, Allife Medical Science and Technology, Global Blood Therapeutics, Inc, Orchard Therapeutics, Acceleron Pharma, Disc Medicine, BRL Medicine, Celgene, and others
- Key Beta Thalassemia Therapies: Mitapivat, CTX00, SLN124, VIT-2763, ACE-536, Emeramide, PTG-300, ICL670, Bitopertin, CTX001, Luspatercept, Deferitrin (GT56-252), HQK-1001, SPD602, and others
- The Beta Thalassemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Beta Thalassemia pipeline products will significantly revolutionize the Beta Thalassemia market dynamics.
Beta Thalassemia Overview
A blood condition known as beta thalassemia (-thalassemia) is characterised by decreased production of the haemoglobin beta chain, which causes microcytic hypochromic anaemia, an abnormal peripheral blood smear with nucleated red blood cells, and decreased haemoglobin A (HbA) levels on haemoglobin analysis.
Get a Free sample for the Beta Thalassemia Market Report
https://www.delveinsight.com/report-store/beta-thalassemia-market
Beta Thalassemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Beta Thalassemia Epidemiology Segmentation:
The Beta Thalassemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Beta Thalassemia
- Prevalent Cases of Beta Thalassemia by severity
- Gender-specific Prevalence of Beta Thalassemia
- Diagnosed Cases of Episodic and Chronic Beta Thalassemia
Download the report to understand which factors are driving Beta Thalassemia epidemiology trends @ Beta Thalassemia Epidemiology Forecast
Beta Thalassemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Beta Thalassemia market or expected to get launched during the study period. The analysis covers Beta Thalassemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Beta Thalassemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Beta Thalassemia Therapies and Key Companies
- Mitapivat: Agios Pharmaceuticals
- CTX001: Vertex Pharmaceuticals Incorporated
- SLN124: Silence Therapeutics
- VIT-2763: Vifor Inc.
- ACE-536: Celgene
- Emeramide: EmeraMed
- PTG-300: Protagonist Therapeutics
- ICL670: Novartis
- Bitopertin: Hoffmann-La Roche
- CTX001: Vertex Pharma
- Luspatercept: Bristol-Myers Squibb
- Deferitrin (GT56-252): Sanofi
- HQK-1001: HemaQuest Pharma
- SPD602: Takeda
Discover more about therapies set to grab major Beta Thalassemia market share @ Beta Thalassemia Treatment Market
Beta Thalassemia Market Strengths
- Increasing investment in R&D among the major players involved in cutting edge drug development technology
- Robust pipeline with well-designed, randomized controlled trials and rising collaborations and agreements between developers
- Increasing prevalence and awareness of beta thalassemia
- Better diagnostic techniques
Beta Thalassemia Market Opportunities
- Lack of any curative treatment options despite the launch of gene therapies which are subject to patient outcome assessment
- The prevalence of thalassemia is expected to rise in the coming years
- Alternative blood sources, such as paid donors or family members
- Improved national blood policies
- Advancement in genetic engineering because gene therapy has been hypothesized to serve as an effective cure for monogenic blood disorders for several decades
Scope of the Beta Thalassemia Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Beta Thalassemia Companies: Novartis, Hoffmann-La Roche, Vertex Pharma, Bristol-Myers Squibb, Sanofi, HemaQuest Pharma, Takeda, Agios Pharmaceuticals, Silence Therapeutics, Vifor Inc., Celgene, EmeraMed, Protagonist Therapeutics, CRISPR Therapeutics, CSL Vifor, EdiGene (GuangZhou) Inc., Ionis Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Silence Therapeutics plc, Phoenicia Biosciences, Shanghai BDgene, Beam Therapeutics, EmeraMed, Regenacy Pharmaceuticals, Editas Medicine, Fulcrum Therapeutics, Allife Medical Science and Technology, Global Blood Therapeutics, Inc, Orchard Therapeutics, Acceleron Pharma, Disc Medicine, BRL Medicine, Celgene, and others
- Key Beta Thalassemia Therapies: Mitapivat, CTX00, SLN124, VIT-2763, ACE-536, Emeramide, PTG-300, ICL670, Bitopertin, CTX001, Luspatercept, Deferitrin (GT56-252), HQK-1001, SPD602, and others
- Beta Thalassemia Therapeutic Assessment: Beta Thalassemia current marketed and Beta Thalassemia emerging therapies
- Beta Thalassemia Market Dynamics: Beta Thalassemia market drivers and Beta Thalassemia market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Beta Thalassemia Unmet Needs, KOL’s views, Analyst’s views, Beta Thalassemia Market Access and Reimbursement
To know more about Beta Thalassemia companies working in the treatment market, visit @ Beta Thalassemia Clinical Trials and Therapeutic Assessment
Table of Contents
1. Beta Thalassemia Market Report Introduction
2. Executive Summary for Beta Thalassemia
3. SWOT analysis of Beta Thalassemia
4. Beta Thalassemia Patient Share (%) Overview at a Glance
5. Beta Thalassemia Market Overview at a Glance
6. Beta Thalassemia Disease Background and Overview
7. Beta Thalassemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Beta Thalassemia
9. Beta Thalassemia Current Treatment and Medical Practices
10. Beta Thalassemia Unmet Needs
11. Beta Thalassemia Emerging Therapies
12. Beta Thalassemia Market Outlook
13. Country-Wise Beta Thalassemia Market Analysis (2019–2032)
14. Beta Thalassemia Market Access and Reimbursement of Therapies
15. Beta Thalassemia Market Drivers
16. Beta Thalassemia Market Barriers
17. Beta Thalassemia Appendix
18. Beta Thalassemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
